

FMC Corp (FMC)

\$110.09 (As of 06/28/21)

Price Target (6-12 Months): **\$116.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 03/22/21)

Prior Recommendation: Underperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:D

Value: C

Growth: F

Momentum: B

Summary

Earnings estimates for FMC Corp for the second quarter of 2021 have been stable over the past month. Strong demand for herbicides and insecticides is likely to support the company's sales in 2021. Moreover, it should gain from its efforts to expand product portfolio through new product launches. New products should drive its top line this year. The acquisition of DuPont's Crop Protection business has also provided a significant growth platform. Synergies from the buyout will drive its earnings. FMC Corp also remains committed to boost shareholders' value and drive free cash flows. However, FMC Corp faces headwinds from higher costs including raw material and logistics, which may hurt margins. Moreover, lower cotton acreage in Brazil and surging coronavirus cases in India may hurt volumes over the near term.


Price, Consensus & Surprise



Data Overview

52-Week High-Low	\$123.66 - \$96.05
20-Day Average Volume (Shares)	785,517
Market Cap	\$14.2 B
Year-To-Date Price Change	-4.2%
Beta	1.00
Dividend / Dividend Yield	\$1.92 / 1.7%
Industry	Chemical - Diversified
Zacks Industry Rank	Top 24% (61 out of 251)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	0.7%
Last Sales Surprise	2.2%
EPS F1 Estimate 4-Week Change	0.0%
Expected Report Date	08/03/2021
Earnings ESP	0.0%

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2022	1,302 E	1,310 E	1,284 E	1,412 E	5,383 E
2021	1,196 A	1,228 E	1,217 E	1,370 E	5,020 E
2020	1,250 A	1,155 A	1,085 A	1,152 A	4,642 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2022	\$1.88 E	\$2.00 E	\$1.85 E	\$2.26 E	\$8.08 E
2021	\$1.53 A	\$1.80 E	\$1.70 E	\$2.15 E	\$7.15 E
2020	\$1.84 A	\$1.72 A	\$1.22 A	\$1.42 A	\$6.19 A

*Quarterly figures may not add up to annual.

P/E TTM	18.7
P/E F1	15.4
PEG F1	1.4
P/S TTM	3.1

The data in the charts and tables, including the Zacks Consensus EPS and sales estimates, is as of 06/28/2021. The report's text and the

analyst-provided price target are as of 06/29/2021.

Overview

Based in Philadelphia, PA, FMC Corporation is an agricultural sciences company offering innovative solutions to farmers globally. It has a robust product portfolio and a development pipeline in crop protection, plant health, and professional pest and turf management.

The company's portfolio includes insect control products based on Rynaxypyr and Cyazypyr active ingredients; Talstar and Hero branded insecticides; Authority, Boral, Centium, Command and Gamit branded herbicides; flutriafol-based fungicides; and biologicals such as Quartzo and Presence bionematicides. The company generated revenues of roughly \$4.6 billion in 2020.


FMC Corp, on Mar 1, 2019, completed the final separation of its Lithium division which has been now rebranded as Livent Corporation. The company spun off its roughly 84% stake in Livent to shareholders of FMC Corp in the form of a pro-rata distribution of Livent shares. The separation marked the transformation of FMC Corp into a pure-play agricultural sciences company.

The company operates through a single business segment that is focused on developing and marketing all three major classes of crop protection chemicals, insecticides, herbicides and fungicides. These products have agricultural applications to increase crop yield and quality by controlling a vast spectrum of insects, weeds and disease.

FMC Corp, in April 2015, purchased Denmark-based Auriga Industries' fully-owned unit, Cheminova A/S, for \$1.8 billion (including debt). Cheminova, which has a strong foothold in Europe and Latin America, develops and markets crop protection products.

The acquisition is a strategic fit for FMC Corp as Cheminova has a highly complementary product portfolio and technologies as well as geographic footprint. Cheminova has a portfolio of more than 60 active ingredients, more than 2,300 registrations and a pipeline of active ingredients currently under development.

FMC Corp, in 2017, completed the purchase of a major portion of DuPont's Crop Protection business. Under the deal terms, FMC Corp purchased DuPont's Cereal Broadleaf Herbicides and Chewing Insecticides portfolios as well as substantially all of the latter's crop protection research and development pipeline.



Reasons To Buy:

▲ FMC Corp is seeing healthy demand for its industry leading products. It is seeing demand strength for its products in North America on strong crop commodity prices. In Asia, demand for herbicides also remain strong in Australia. The company saw higher demand for diamides and other insecticides in specialty crops in Asia in 2020. Demand for the company's products in sugarcane and soybean applications was also strong in Brazil in 2020 and is expected to continue this year. FMC Corp sees global crop protection market to be up low-single digits in 2021 with crop commodity prices improving and the impacts of the coronavirus pandemic reducing on crop demand. The company expects strong volume growth in 2021, led by Asia, Latin America and EMEA (Europe, Middle East, and Africa).

FMC Corp will benefit from its efforts to expand product portfolio and acquisitions. Strong demand for herbicides and insecticides should also drive its sales.

▲ FMC Corp remains committed to expand its market position and strengthen its portfolio. Continued market share gains and new product introductions (across corn, soybean and cotton markets) in North and Latin America are expected to support results in the company's agricultural business. The company remains focused on investing in technologies and products in its agriculture business and launching new products with a goal to enhance value to the farmers. The company remains committed to invest in its research and development (R&D) pipeline to bring new technologies to customers plans and expects its R&D spending to increase by roughly \$14 million year over year in 2021. New product launches in Europe, North America and Asia are contributing to volume growth. The company expects new products such as the Overwatch herbicide and the Xyway fungicide to make significant contribution in 2021. It expects new products to contribute \$400 million (including \$100 million from products launched in 2021) in sales this year.

▲ The company maintains a strategy of growth through acquisitions. The acquisition of Cheminova has expanded FMC Corp.'s access in major agricultural end markets. Moreover, the recently completed acquisition of a major portion of DuPont's Crop Protection business has provided a significant growth platform for the company's Agricultural Solutions unit. The buyout will make the Agricultural Solutions unit the fifth biggest crop protection chemical company in the world by sales and will significantly increase the company's presence in Asia and Europe. The acquisition should contribute to the company's revenues and earnings.

▲ FMC Corp remains committed to return value to shareholders leveraging healthy cash flows. It generated free cash flow of \$544 million in 2020, up 80% year over year. The company, in late 2020, raised its quarterly dividend by 9% to 48 cents per share. It returned around \$343 million to shareholders through dividends (of nearly \$230 million) and share repurchases in 2020. The company expects to generate significant free cash flow (of \$530-\$620 million) in 2021 and maintain its dividend payout. FMC Corp expects to buyback stock worth \$400-\$500 million and pay dividends of nearly \$250 million in 2021, with total cash deployment is anticipated to be roughly \$700 million or above for the year. The company returned \$137 million to shareholders in the most recent quarter through dividend and share repurchases. The company also ended the first quarter of 2021 with cash of roughly \$416.7 million, which appears to be adequate to meet its short-term debt obligations. Further, its time-interest-earned ratio of 5.9 at the end of the first quarter rose from 5.8 in the prior quarter. As such, the company appears to have a lower default risk.

Reasons To Sell:

- ▼ FMC Corp's shares are up 12.5% over the past year, underperforming the industry's rise of 50%. The company faces challenges from higher supply chain costs including logistics and certain raw materials costs, partly due to supply disruptions from production issues in countries like China and India amid the coronavirus outbreak. It is seeing rising costs for some raw materials and active ingredients due to supply constraints. The company expects cost headwind of \$40-\$50 million associated with raw material and logistics cost increases in 2021.
- ▼ The company is also exposed to cost headwinds stemming from higher R&D investments in 2021. It sees \$30-\$40 million cost headwind on its adjusted EBITDA related to incremental R&D spending. Moreover, the company expects an increase in its selling, general and administrative expenses. As such, higher costs are likely to hurt the its margins.
- ▼ FMC Corp faced volume pressure in the most recent quarter. Volumes declined 4% in the quarter, hurt by a decline in cotton acreage in Brazil and discontinued registrations in the EMEA. Prevailing softness in the cotton business in Brazil, as reflected by reduced acreage demand, is expected to be a headwind for the company through the first half of 2021. A significant increase in coronavirus cases in India and Brazil may also impact agricultural markets across these countries over the near term and hurt demand for the company's products.

FMC Corp is exposed to headwinds from higher raw material and logistic costs. Lower cotton acreage in Brazil will also exert pressure on its volumes.

Last Earnings Report

FMC Corp's Earnings and Revenues Surpass Estimates in Q1

FMC Corp recorded earnings (as reported) of \$1.40 per share in first-quarter 2021, down from \$1.58 reported a year ago.

Barring one-time items, adjusted earnings per share were \$1.53, beating the Zacks Consensus Estimate of \$1.52.

Revenues were \$1,195.6 million for the quarter, down 4% from the year-ago quarter. It, however, surpassed the Zacks Consensus Estimate of \$1,170.3 million.

The decline in revenues was due to 4% lower volumes and 1% pricing headwind, partly offset by 1% favorable impact of currencies. The company saw lower sales across EMEA, North America and Latin America, partly offset by gains in Asia.

Regional Sales Performance

Sales dropped 8% year over year in North America in the quarter as a shift of diamide third-party partner sales from North America to Latin America more than offset higher sales for herbicides and a strong launch of Xyway fungicide.

Sales in Latin America slipped 22% year over year in the reported quarter due to currency headwinds, lower cotton planting and the company's channel inventory management.

In EMEA, sales fell 4% year over year, partly due to discontinued registrations. The company witnessed higher insecticide sales in the quarter.

Revenues climbed 18% year over year in Asia on the back of strong demand for Overwatch herbicide in Australia and higher diamide demand in the region.

Financials

The company had cash and cash equivalents of \$416.7 million at the end of the quarter, down roughly 4% year over year. Long-term debt was \$2,631.4 million, down around 25% year over year.

The company repurchased shares worth \$75 million in the first quarter.

Guidance

For 2021, FMC continues to expect revenues to be between \$4.9 billion and \$5.1 billion, indicating a rise of 8% at the midpoint versus 2020. The growth is expected to be driven mainly by volumes and price increases.

Moreover, FMC envisions adjusted EBITDA of \$1.32-\$1.42 billion for 2021, indicating a 10% rise at the midpoint versus 2020.

The company has raised its adjusted earnings per share forecast for 2021 to the range of \$6.70-\$7.40 (up from \$6.65-\$7.35 expected earlier), reflecting an increase of 14% at the midpoint compared with 2020.

Free cash flow for 2021 is projected to be \$530-\$620 million, indicating a 6% year-over-year increase.

The company also expects to buyback \$400-\$500 million shares in 2021.

For second-quarter 2021, revenues are projected in the band of \$1.19-\$1.26 billion, reflecting an increase of 6% at the midpoint compared with the prior-year quarter. Adjusted earnings are forecast in the range of \$1.68-\$1.88 per share, representing an increase of 3% at the midpoint compared with the prior-year quarter.

Quarter Ending	03/2021
Report Date	May 05, 2021
Sales Surprise	2.17%
EPS Surprise	0.66%
Quarterly EPS	1.53
Annual EPS (TTM)	5.89

Recent News

FMC Corp Obtains U.S. EPA Approval for Fluindapyr

FMC Corp, on **Jun 8, 2021**, received the U.S. Environmental Protection Agency (EPA) registration for fluindapyr, a new succinate dehydrogenase inhibitor (SDHI) fungicide. It provides an extensive range of activity against a wide range of destructive diseases in row and specialty crops besides turf.

This registration marks the first major regulatory approval for fluindapyr. The company has also submitted for registration of this fungicide in multiple regions, including China, the European Union, Brazil and Argentina.

The grant of these registrations will give global access to this fungicide to farmers, to inhibit various fungal diseases in row crops, including rust diseases, and powdery mildew in specialty crops. There is also evidence suggesting that fluindapyr controls pathogens that are resistant to other chemicals.

Additionally, the U.S. golf course superintendents can address destructive turf diseases such as Bipolaris Leaf Spot, Take-All Root Rot, Large Patch, Anthracnose, Fairy Ring and Dollar Spot with FMC's new Kalida fungicide that is effective in the management of turfgrass diseases to achieve outstanding results. Notably, Kalida is a combination of fluindapyr and flutriafol.

FMC stated that fluindapyr is the outcome of 10 years of research and development. The company is optimistic that its offering of high-performance fluindapyr premixture products will provide growers and golf course superintendents with an effective fungicide with superior performance that is also compatible with the best disease management techniques.

FMC fluindapyr brands will enable growers across the world to provide tailored programs, treat a variety of crops and multiple diseases that often attack the crops at the same time, and export their crops freely.

Valuation

FMC Corp's shares are up 12.5% over the trailing 12-month period. Over the past year, the Zacks Chemical - Diversified industry and the Zacks Basic Materials sector are up 50% and up 46.7%, respectively.

The S&P 500 index is up 40.5% in the past year.

The stock is currently trading at 14.69X forward 12-month earnings, which compares to 13.84X for the Zacks sub-industry, 9.5X for the Zacks sector and 21.82X for the S&P 500 index.

Over the past five years, the stock has traded as high as 36.36X and as low as 8.78X, with a 5-year median of 15.09X.

Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$116 price target reflects 15.49X forward 12-month earnings per share.

The table below shows summary valuation data for FMC:

Valuation Multiples - FMC					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	14.69	13.84	9.5	21.82
	5-Year High	36.36	18.82	17.95	23.83
	5-Year Low	8.78	8.7	9.5	15.31
	5-Year Median	15.09	13.16	12.83	18.05
EV/EBITDA TTM	Current	14.09	11.62	8.28	17.59
	5-Year High	28.64	12.76	17.8	17.74
	5-Year Low	8.63	5.14	6.54	9.63
	5-Year Median	13.5	7.56	9.31	13.48
P/B TTM	Current	4.76	2.7	3.41	7.12
	5-Year High	6.09	2.86	3.68	7.12
	5-Year Low	2.89	0.83	1.22	3.84
	5-Year Median	4.14	1.69	2.26	5.02

As of 06/28/2021

Source: Zacks Investment Research

Industry Analysis Zacks Industry Rank: Top 24% (61 out of 251)



Top Peers

Company (Ticker)	Rec	Rank
Avient Corporation (AVNT)	Outperform	1
Olin Corporation (OLN)	Outperform	1
Tronox Holdings PLC (TROX)	Outperform	1
Albemarle Corporation (ALB)	Neutral	3
The Chemours Company (CC)	Neutral	2
Huntsman Corporation (HUN)	Neutral	3
UBE Industries, Ltd. Un-sponsored ADR (UBEOY)	Neutral	3
TOKUYAMA CORP (TKYMY)	Underperform	5

The positions listed should not be deemed a recommendation to buy, hold or sell.

Industry Comparison Industry: Chemical - Diversified				Industry Peers		
	FMC	X Industry	S&P 500	CC	OLN	UBEOY
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Outperform	Neutral
Zacks Rank (Short Term)	3	-	-	2	1	3
VGM Score	D	-	-	A	B	A
Market Cap	14.19 B	4.31 B	30.38 B	5.66 B	7.41 B	2.30 B
# of Analysts	7	3	12	4	4	1
Dividend Yield	1.74%	1.45%	1.34%	2.92%	1.72%	1.45%
Value Score	C	-	-	A	B	A
Cash/Price	0.03	0.09	0.06	0.17	0.03	0.33
EV/EBITDA	15.71	11.84	17.31	12.01	20.07	NA
PEG F1	1.39	1.12	2.10	0.41	NA	NA
P/B	4.68	2.29	4.06	6.64	4.36	0.64
P/CF	14.65	11.11	17.45	8.55	6.96	4.07
P/E F1	15.32	14.55	21.17	10.85	8.47	9.77
P/S TTM	3.09	1.15	3.39	1.12	1.19	0.40
Earnings Yield	6.49%	6.83%	4.62%	9.21%	11.81%	10.23%
Debt/Equity	0.87	0.48	0.66	4.66	2.18	0.44
Cash Flow (\$/share)	7.51	3.00	6.86	4.00	6.67	2.67
Growth Score	F	-	-	C	A	A
Historical EPS Growth (3-5 Years)	27.41%	-0.60%	9.59%	12.44%	2.87%	NA
Projected EPS Growth (F1/F0)	15.56%	45.20%	21.79%	59.09%	506.30%	0.00%
Current Cash Flow Growth	1.88%	-9.87%	1.02%	-10.96%	51.56%	-5.50%
Historical Cash Flow Growth (3-5 Years)	18.87%	0.30%	7.34%	9.50%	26.98%	NA
Current Ratio	1.38	1.89	1.39	1.86	1.65	1.65
Debt/Capital	46.47%	32.70%	41.51%	82.33%	68.60%	30.36%
Net Margin	11.51%	4.30%	12.06%	4.25%	-10.34%	3.76%
Return on Equity	26.00%	10.06%	16.59%	43.27%	5.74%	6.59%
Sales/Assets	0.45	0.73	0.51	0.72	0.74	0.82
Projected Sales Growth (F1/F0)	8.14%	10.67%	9.56%	16.57%	36.84%	-1.95%
Momentum Score	B	-	-	A	D	F
Daily Price Change	-1.71%	-0.43%	0.23%	-2.06%	-0.39%	0.00%
1-Week Price Change	-0.03%	1.48%	1.56%	6.27%	5.21%	0.00%
4-Week Price Change	-5.66%	-4.95%	2.06%	-4.84%	-4.93%	0.00%
12-Week Price Change	-3.29%	-1.44%	5.22%	17.94%	17.31%	-6.38%
52-Week Price Change	13.13%	45.37%	40.53%	123.32%	312.06%	2.24%
20-Day Average Volume (Shares)	785,517	154,690	1,986,546	1,346,105	1,198,032	0
EPS F1 Estimate 1-Week Change	-0.10%	0.00%	0.00%	1.07%	0.00%	0.00%
EPS F1 Estimate 4-Week Change	0.04%	0.00%	0.00%	1.07%	0.92%	0.00%
EPS F1 Estimate 12-Week Change	0.37%	7.41%	3.61%	16.52%	70.03%	-2.63%

Past performance is no guarantee of future results. Please see important disclosures and definitions at the end of this report.

EPS Q1 Estimate Monthly Change	0.00%	0.00%	0.00%	4.35%	0.59%	NA
--------------------------------	-------	-------	-------	-------	-------	----

Source: Zacks Investment Research

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we maintain a balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Value Score	C
Growth Score	F
Momentum Score	B
VGM Score	D

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.

Additional Disclosure

This material represents an assessment of the market and economic environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. Forward-looking statements are subject to certain risks and uncertainties. Any statements that refer to expectations, projections or characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Actual results, performance, or achievements may differ materially from those expressed or implied.

Returns quoted represent past performance which is no guarantee of future results. Investment returns and principal value will fluctuate so that when shares are redeemed, they may be worth more or less than their original cost. Current performance may be higher or lower than the performance shown.

Investing involves risk; principal loss is possible. There is no guarantee that companies that can issue dividends will declare, continue to pay or increase dividends.

Glossary of Terms and Definitions

52-Week High-Low: The range of the highest and lowest prices at which a stock has traded during the past year. This range is determined based on the stock's daily closing price which may differ from the intra-day high or low. Many investors use it as a technical indicator to determine a stock's current value and future price movement. The idea here is that if price breaks out from the 52-week range, in either direction, the momentum may continue in the same direction.

20-Day Average Volume (Shares): The average number of shares of a company traded in a day over the last 20 days. It is a direct indication of a security's overall liquidity. The higher the average daily trading volume, the easier it is to enter or exit the stock at a desired price with more buyers and sellers being available.

Daily Price Change: This is the percentage difference between a trading day's closing price and the prior trading day's closing price. This item is updated at 9 p.m. EST each day.

1-Week Price Change: This is the percentage change in a stock's closing price over the last 5 trading days. This change reflects the collective buying and selling sentiment over the 1-week period.

A strong weekly price increase for the stock, especially when accompanied by increased volume, is an indication of it gaining momentum.

4-Week Price Change: This is the percentage change in a stock's closing price over the last 20 trading days or past 4 weeks. This is a medium-term price change metric and an indication of the stock gaining momentum.

12-Week Price Change: This is the percentage change of a stock's closing price over the last 60 trading days or past 12 weeks. Similar to 4-week price change, this is a medium-term price change metric. It shows whether a stock has been enjoying strong investor demand, or if it has been in consolidation, or distress over this period.

52-Week Price Change: This is the percentage change in a stock's closing price over the last 260 trading days or past 52 weeks. This long-term price change metric is a good reference point for investors. Some investors seek stocks with the best percentage price change over the last 52 weeks, expecting the momentum to continue.

Market Cap: The number of outstanding common shares of a company times its latest price per share. This figure represents a company's size, which indicates various characteristics, including price stability and risk, in which investors could be interested.

Year-To-Date Price Change: Change in a stock's daily closing price in the period of time beginning the first day of the current calendar year through to the previous trading day.

of Analysts: Number of EPS estimates used in calculating the current-quarter consensus. These estimates come from the brokerage analysts tracking this stock. However, the number of such analysts tracking this stock may not match the number of estimates, as all brokerage analysts may not come up with an estimate or provide it to us.

Beta: A measure of risk commonly used to compare the volatility of a stock to the overall market. The S&P 500 Index is the base for calculating beta and carries a value of 1. A stock with beta below 1 is less risky than the market as a whole. And a stock with beta above 1 is riskier.

Dividend: The portion of earnings a company is expected to distribute to its common shareholders in the next 12 months for each share they own. Dividends are usually paid quarterly. Dividend payments reflect positively on a company and help maintain investors' trust. Investors typically find dividend-paying stocks appealing because the dividend adds to any market price appreciation to result in higher return on investment (ROI). Moreover, a steady or increasing dividend payment provides investors a cushion in a down market.

Dividend Yield: The ratio of a company's annual dividend to its share price. The annual dividend used in the ratio is calculated based on the most recent dividend paid by the company. Dividend yield is an estimate of the dividend-only return from a stock in the next 12 months. Since dividend itself doesn't change frequently, dividend yield usually changes with a stock's price movement. As a result, often an unusually high dividend yield is a result of weak stock price.

S&P 500 Index: The Standard & Poor's 500 (S&P 500) Index is an unmanaged group of securities considered to be representative of the stock market in general. It is a market-capitalization-weighted index of stocks of the 500 largest U.S. companies. Each stock's weight in the index is

proportionate to its market value.

Industry: One of the 250+ groups that Zacks classifies all stocks into based on the nature of business. These groups are termed as expanded (aka "X") industries and map to their respective (economic) sectors; Zacks has 16 sectors.

Zacks Industry Rank: The Zacks Industry Rank is determined by calculating the average Zacks Rank for all stocks in the industry and then assigning an ordinal rank to it. For example, an industry with an average Zacks Rank of 1.6 is better than an industry with an average Zacks Rank of 2.3. So, the industry with the better average Zacks Rank would get a better Zacks Industry Rank. If an industry has the best average Zacks Rank, it would be considered the top industry (1 out of 250+), which would place it at the top 1% of Zacks-ranked industries. Studies have shown that roughly half of a stock's price movement can be attributed to the industry group it belongs to. In fact, the top 50% of Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.

Last EPS Surprise: The percentage deviation of a company's last reported earnings per share from the Zacks Consensus Estimate. Companies with a positive earnings surprise are more likely to surprise again in the future (or miss again if they recently missed).

Last Sales Surprise: The percentage deviation of a company's last reported sales from the Zacks Consensus Estimate.

Expected Report Date: This is an estimated date of a company's next earnings release. The information originated or gathered by Zacks Investment Research from its information providers or publicly available sources is the basis of this estimate.

Earnings ESP: The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the yet-to-be reported quarter. The Most Accurate Estimate is the most recent version of the Zacks Consensus EPS Estimate. The idea here is that analysts revising their estimates closer to an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time.

Periods:

TTM: Trailing 12 months. Using TTM figures is an effective way of analyzing the most-recent financial data in an annualized format that helps neutralize the effects of seasonality and other quarter-to-quarter variation.

F1: Current fiscal year. This period is used to analyze the estimates for the ongoing full fiscal year.

F2: Next fiscal year. This period is used to analyze the estimates for the next full fiscal year.

F12M: Forward 12 months. Using F12M figures is an effective way of analyzing the near-term (the following four unreported quarters) estimates in an annualized manner. Instead of typically representing estimates for the full fiscal year, which may not represent the nitty-gritty of each quarter, F12M figures suggest an all-inclusive annualized estimate for the following four quarters. The annualization helps neutralize the potential effects of seasonality and other quarter-to-quarter variations.

P/E Ratio: The price-to-earnings ratio measures a company's current market price per share relative to its earnings per share (EPS). Usually, the trailing-12-month (TTM) EPS, current-fiscal-year (F1) EPS estimate, or forward-12-month (F12M) EPS estimate is used as the denominator. In essence, this ratio shows what the market is willing to pay today for each dollar of EPS. In other words, this ratio gives a sense of what the relative value of the company is at the already reported level of earnings or at a future level of earnings.

It is one of the most widely-used multiples for determining the value of a company and helps comparing its valuation with that of a competitor, the industry group or a benchmark.

PEG Ratio: The price/earnings to growth ratio is a stock's P/E ratio using current fiscal year (F1) EPS estimate divided by its expected EPS growth rate over the coming 3 to 5 years. This ratio essentially determines a stock's value by factoring in the company's expected earnings growth and is thus believed to provide a more complete picture than just the P/E ratio, particularly for faster-growing companies.

P/S Ratio: The price-to-sales ratio is calculated as a company's current price per share divided by trailing 12 months (TTM) sales or revenues per share. This ratio shows what the market is willing to pay today for each dollar of TTM sales per share. The P/S ratio is at times the only valuation metric when the company has yet to become profitable.

Cash/Price Ratio: The cash-to-price ratio or Cash Yield is calculated as cash and marketable securities per share divided by the company's current share price. Like the earnings yield, which shows the anticipated yield (or return) on a stock from earnings for each dollar invested, the cash yield does the same, with cash being the source of return instead of earnings. For example, a cash/price ratio of 0.08 suggests a return of 8% or 8 cents for every \$1 investment.

EV/EBITDA Ratio: The EV/EBITDA ratio, also known as Enterprise Multiple, is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by EBITDA (earnings before interest, taxes, depreciation and amortization). Usually, trailing-12-month (TTM) or forward-12-month (F12M) EBITDA is used as the denominator.

EV/Sales Ratio: The enterprise value-to-sales ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by annual sales. It is an expansion of the P/S valuation, which uses market value instead of enterprise value. The EV/Sales ratio is perceived as more accurate than P/S, in part, because the market capitalization does not take a company's debt into account when valuing it.

EV/CF Ratio: The enterprise value-to-cash flow ratio is calculated as a company's enterprise value (market capitalization + value of total long-

term debt + book value of preferred shares - cash and marketable securities) divided by the trailing-12-month (TTM) operating cash flow. It's a measure of how long it would take to buy the entire business if you were able to use all the company's operating cash flow.

The EV/CF ratio is perceived as more accurate than the P/CF ratio, in part, because the market price does not take a company's debt into account when valuing it.

EV/FCF Ratio: The enterprise value-to-free cash flow metric compares a company's enterprise value to its trailing-12-month (TTM) free cash flow (FCF). This metric is very similar to the EV/CF ratio, but is considered a more exact measure owing to the fact that it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding growth activities and payments to shareholders.

P/EBITDA Ratio: The P/EBITDA ratio is calculated as a company's per share market value divided by EBITDA (earnings before interest, taxes, depreciation, and amortization). This metric is very similar to the EV/EBITDA ratio, but is considered a little less exact measure as it uses market price, which does not take a company's debt into account. However, since EBITDA is often considered a proxy for cash income, the metric is used as a measure of what the market is willing to pay today for each dollar of the company's cash profitability in the trailing 12 months (TTM) or forward 12 months (F12M).

P/B Ratio: The price-to-book ratio is calculated as a company's current price per share divided by its book value (total assets – liabilities – preferred stocks) per share. In short, the book value is how much a company is worth. In other words, it reflects the total value of a company's assets that its common shareholders would receive if it were to be liquidated. So, the P/B ratio indicates whether you're paying higher or lower than what would remain if the company went bankrupt immediately. Investors typically use this metric to determine how a company's stock price stacks up to its intrinsic value.

P/TB Ratio: The price-to-tangible-book value ratio is calculated as the per share market value of a company divided by the value of its tangible assets (total assets – liabilities – preferred stocks – intangible assets) per share. Tangible book value is the same thing as book value except it excludes the value of intangible assets to get a step closer to the baseline value of the company.

P/CF Ratio: The price-to-cash flow ratio measures a company's per share market price relative to its trailing-12-month (TTM) operating cash flow per share. This metric is used to determine whether a company is undervalued or overvalued relative to another stock, industry or sector. And like the P/E ratio, a lower number is typically considered better from the value perspective.

One of the reasons why P/CF ratio is often preferred over P/E ratio is the fact that operating cash flow adds back non-cash expenses such as depreciation and amortization to net income. This feature helps valuing stocks that have positive cash flow but are not profitable because of large noncash charges.

P/FCF Ratio: The price-to-free cash flow ratio is an extension of P/CF ratio, which uses trailing-12-month (TTM) free cash flow per share instead of operating cash flow per share. This metric is considered a more exact measure than P/CF ratio, as free cash flow subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding activities that generate additional revenues.

Earnings Yield: The earnings yield is calculated as current fiscal year (F1) EPS estimate divided by the company's current share price. The ratio, which is the inverse of the P/E ratio, measures the anticipated yield (or return) from earnings for each dollar invested in a stock today.

For example, earnings yield for a stock, which is trading at \$35 and expected to earn \$3 per share in the current fiscal year (F1), would be 0.0857 ($3/35 = 0.0857$) or 8.57%. In other words, for \$1 invested in the stock today, the yield from earnings is anticipated to be 8.57 cents.

Investors most commonly compare the earnings yield of a stock to that of a broad market index (such as the S&P 500) and prevailing interest rates, such as the current 10-year Treasury yield. Since bonds and stocks compete for investors' dollars, stock investors typically demand a higher yield for the extra risk they assume compared to investors of U.S. Treasury-backed securities that offer virtually risk-free returns. This additional return is referred to as the risk premium.

Debt/Equity Ratio: The debt-to-equity ratio is calculated as a company's total liabilities divided by its shareholder equity. This metric is used to gauge a company's financial leverage. In other words, it is a measure of the degree to which a company is financing its operations through debt versus its own funds. The higher the ratio, the higher the risk for shareholders.

However, this ratio is difficult to compare across industry groups where ideal amounts of debt vary. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-equity ratio should be compared with other companies in the same industry.

Cash Flow (\$/share): Cash flow per share is calculated as operating cash flow (after-tax earnings + depreciation + other non-cash charges) divided by common shares outstanding. It is used by many investors as a measure of a company's financial strength. Since cash flow per share takes into consideration a company's ability to generate cash by adding back non-cash expenses, it is regarded by some as a more accurate measure of a company's financial situation than earnings per share, which could be artificially deflated.

Current Ratio: The current ratio or liquidity ratio is a company's current assets divided by its current liabilities. It measures a company's ability to pay short-term obligations. A current ratio that is in line with the industry average or slightly higher is generally considered acceptable. A current ratio that is lower than the industry average would indicate a higher risk of distress or default. A higher number is usually better. However, a very high current ratio compared to the industry average could be an indication of inefficient use of assets by management.

Debt/Capital Ratio: Debt-to-capital ratio is a company's total debt (interest-bearing debt + both short- and long-term liabilities) divided its total capital (interest-bearing debt + shareholders' equity). It is a measure of a company's financial leverage. All else being equal, the higher the debt-to-capital ratio, the riskier the stock.

However, this ratio can vary widely from industry to industry, the ideal amount of required debt being different. Some businesses are more capital

intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-capital ratio should be compared with the same for its industry.

Net Margin: Net margin is calculated as net income divided by sales. It shows how much of each dollar in sales generated by a company translates into profit. For example, if a company's net margin is 15%, its net income is 15 cents for every \$1 of sales it makes.

A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. If a company's expenses are growing faster than sales, its net margin will decline. However, different net margin rates are considered good for different industries, so it's better to compare net margin rates of companies in the same industry group.

Return on Equity: Return on equity (ROE) is calculated as trailing-12-month net income divided by trailing-12-month average shareholder equity (including reinvested earnings). This metric is considered a measure of how effectively management is using a company's assets to generate profits. For example, if a company's ROE is 10%, it creates 10 cents profits for every \$1 shareholder equity, which is basically the company's assets minus debt. A company's ROE deemed good or bad depends on what's normal for its peers or industry group.

Sales/Assets Ratio: The sales-to-assets ratio or asset utilization ratio or asset turnover ratio is calculated as a company's annual sales divided by average assets (average of assets at the beginning of the year and at the year's end). This metric helps investors understand how effectively a company is using its assets to generate sales. For example, a sales-to-assets ratio of 2.5 indicates that the company generated \$2.50 in sales for every \$1 of assets on its books.

The higher the sales-to-assets ratio, the better the company is performing. However, similar to many other ratios, the asset turnover ratio tends to be higher for companies in certain industries/sectors than in others. So, a company's sales-to-assets ratio should be compared with the same for its industry/sector.

Historical EPS Growth (3-5 Years): This is the average annual (trailing-12-month) EPS growth rate over the last 3-5 years. This metric helps investors see how a company's EPS has grown from a long-term perspective.

Note: There are many factors that can influence short-term numbers — a recession will reduce this number, while a recovery will inflate it. The longterm perspective helps smooth out short-term events.

Projected EPS Growth (F1/F0): This is the estimated EPS growth rate for the current financial year. It is calculated as the consensus estimate for the current fiscal year (F1) divided by the reported EPS for the last completed fiscal year (F0).

Current Cash Flow Growth: It measures the latest year-over-year change in operating cash flow. Cash flow growth tells an investor how quickly a company is generating inflows of cash from operations. A positive change in the cash flow is desired and shows that more 'cash' is coming in than going out.

Historical Cash Flow Growth (3-5 Years): This is the annualized change in cash flow over the last 3-5 years. The change in a longer period helps put the current reading into proper perspective. By looking at the rate, rather than the actual dollar value, the comparison across the industry and peers becomes easier.

Projected Sales Growth (F1/F0): This metric looks at the estimated sales growth for the current year. It is calculated as sales estimate for the current fiscal year (F1) divided by the reported sales for the last completed fiscal year (F0).

Like EPS growth, a higher rate is better for sales growth. A look at a company's projected sales growth instantly tells you what the outlook is for their products and services. However, different sales growth rates are considered good for different industries, so it's better to compare sales growth rates of companies in the same industry group.

EPS F1 Estimate 1-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past week. The change in a company's consensus EPS estimate (or earnings estimate revision) has proven to be strongly correlated with the near-term price movement of its shares. It is an integral part of the Zacks Rank.

If a stock's consensus EPS estimate is \$1.10 now versus \$1.00 a week ago, that will be reflected as a 10% upward revision. If, on the other hand, it went from \$1.00 to 90 cents, that would be a 10% downward revision.

EPS F1 Estimate 4-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past four weeks.

A stock's earnings estimate revision in a 1-week period is important. But it's more meaningful to look at the longer-term revision. And, of course, the 4-week change helps put the 1-week change into proper perspective.

EPS F1 Estimate 12-Week Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past 12 weeks.

This metric essentially shows how the consensus EPS estimate has changed over a period longer than 1 week or 4 weeks.

EPS Q1 Estimate Monthly Change: The percentage change in the Zacks Consensus EPS estimate for the current fiscal quarter over the past four weeks.

While the revision in consensus EPS estimate for the current fiscal year is strongly correlated with the near-term price movement of its shares, the estimate revision for the current fiscal quarter is an important metric as well, especially over the short term, and particularly as a stock approaches its earnings date. If a stock's Q1 EPS estimate decreases ahead of its earnings release, it's usually a negative sign, whereas an increase is a positive sign.